Market revenue in 2023 | USD 6,441.1 million |
Market revenue in 2030 | USD 11,774.8 million |
Growth rate | 9% (CAGR from 2023 to 2030) |
Largest segment | Transdermal patches |
Fastest growing segment | Infusion Pumps |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Photodynamic Therapy Devices, Transdermal Patches, Wound Care Products, Infusion Pumps, Orthopedic Combination Products, Drug Eluting Stents, Inhalers, Antimicrobial Catheters |
Key market players worldwide | Abbott Laboratories, Terumo Corp, Stryker Corp, Viatris Inc, Medtronic PLC, Boston Scientific Corp, Novartis AG ADR, Becton Dickinson & Co, Teleflex Inc, W L Gore & Associates |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug device combination products market will help companies and investors design strategic landscapes.
Transdermal patches was the largest segment with a revenue share of 23.25% in 2023. Horizon Databook has segmented the India drug device combination products market based on photodynamic therapy devices, transdermal patches, wound care products, infusion pumps, orthopedic combination products, drug eluting stents, inhalers, antimicrobial catheters covering the revenue growth of each sub-segment from 2018 to 2030.
India’s relatively liberal laws governing the use of medical devices and increasing healthcare spending are among the main factors driving the adoption of drug-device combination products. In addition, the opening of new corporate hospitals, the introduction of organized training programs, and awareness campaigns related to drug-device combination products are expected to propel market growth over the forecast period.
India is one of the top three countries in terms of diabetes prevalence. According to WHO, in 2021, nearly 77 million people were living with diabetes in India, and an estimated 8.7% of people with diabetes were aged between 20 and 70 years. Indians are more likely to develop diabetes than people in other parts of the world, such as the Americas & Europe. This is due to the Indian diet being high in carbohydrates and saturated fats, which adds more sugar & calories to the body than it needs.
In addition, the growing prevalence of sedentary lifestyles and obesity are contributing to the high prevalence of diabetes. Hence, the high prevalence of chronic diseases in India is expected to drive the demand for drug-device combination products during the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the India drug device combination products market , including forecasts for subscribers. This country databook contains high-level insights into India drug device combination products market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account